MX370416B - Formulaciones con oxidacion reducida. - Google Patents

Formulaciones con oxidacion reducida.

Info

Publication number
MX370416B
MX370416B MX2015011433A MX2015011433A MX370416B MX 370416 B MX370416 B MX 370416B MX 2015011433 A MX2015011433 A MX 2015011433A MX 2015011433 A MX2015011433 A MX 2015011433A MX 370416 B MX370416 B MX 370416B
Authority
MX
Mexico
Prior art keywords
formulations
protein
methods
oxidation
reduced oxidation
Prior art date
Application number
MX2015011433A
Other languages
English (en)
Other versions
MX2015011433A (es
Inventor
Sreedhara Alavattam
Mary Mallaney
Parbir Grewal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2015011433A publication Critical patent/MX2015011433A/es
Publication of MX370416B publication Critical patent/MX370416B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Lubricants (AREA)

Abstract

La presente invención se refiere a formulaciones que comprenden una proteína en combinación con un compuesto que impide la oxidación de la proteína. La invención también proporciona métodos para elaborar estas formulaciones y métodos para usar estas formulaciones. La invención proporciona además métodos para examinar compuestos para impedir la oxidación de una proteína en una composición de proteína y métodos para prevenir la oxidación de una proteína en una formulación.
MX2015011433A 2013-03-13 2014-03-13 Formulaciones con oxidacion reducida. MX370416B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780852P 2013-03-13 2013-03-13
US201361909850P 2013-11-27 2013-11-27
PCT/US2014/026850 WO2014160497A1 (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Publications (2)

Publication Number Publication Date
MX2015011433A MX2015011433A (es) 2016-04-27
MX370416B true MX370416B (es) 2019-12-10

Family

ID=51625443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011433A MX370416B (es) 2013-03-13 2014-03-13 Formulaciones con oxidacion reducida.

Country Status (19)

Country Link
EP (1) EP2968467B1 (es)
JP (2) JP6606059B2 (es)
KR (2) KR102238379B1 (es)
CN (1) CN105209058A (es)
BR (1) BR112015022475A8 (es)
CA (2) CA2904169C (es)
DK (1) DK2968467T3 (es)
ES (1) ES2808823T3 (es)
HK (1) HK1212613A1 (es)
HR (1) HRP20201161T1 (es)
HU (1) HUE049707T2 (es)
LT (1) LT2968467T (es)
MX (1) MX370416B (es)
PL (1) PL2968467T3 (es)
PT (1) PT2968467T (es)
RS (1) RS60534B1 (es)
RU (2) RU2019137020A (es)
SI (1) SI2968467T1 (es)
WO (1) WO2014160497A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827846B1 (en) 2015-08-18 2024-10-02 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
WO2017031363A2 (en) * 2015-08-18 2017-02-23 Aspyrian Therapeutics, Inc. Methods for manufacturing phthalocyanine dye conjugates and stable conjugates
CA3106537A1 (en) * 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
CA2086417C (en) 1990-06-29 1999-07-06 Biosource Technologies, Inc. Melanin production by transformed organisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
RU2134120C1 (ru) * 1995-06-26 1999-08-10 Безруков Михаил Васильевич Средство для стабилизации пептидной связи в белковом препарате
EP0921855B1 (en) 1996-08-30 2003-11-19 Upfront Chromatography A/S Isolation of immunoglobulins
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
DK1167537T3 (da) 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001024814A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
JP2001165858A (ja) * 1999-12-06 2001-06-22 Bunshi Biophotonics Kenkyusho:Kk 5−アルコキシインドール類の測定方法及び装置
CA2447114A1 (en) 2001-05-16 2002-11-21 Abgenix, Inc. Human antipneumococcal antibodies from non-human animals
ATE531390T1 (de) 2001-08-23 2011-11-15 Genmab As Interleukin-15-(il-15-)spezifische menschliche antikörper
EP1539212A4 (en) * 2002-07-12 2007-05-02 Medarex Inc METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS
EP1590434A4 (en) 2003-01-17 2006-11-29 Univ New York State Res Found ASSOCIATED ANTIGEN, ANTIBODIES, AND DIAGNOSIS AND TREATMENT METHODS WITH CONCENTRATED CANNULA CANCER
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP4999158B2 (ja) 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌(bachillusanthracis)の感染防御抗原に対するヒトモノクローナル抗体
CN101074208A (zh) * 2007-06-29 2007-11-21 方炳良 吲哚衍生物的制备方法
RU2414237C2 (ru) * 2008-04-30 2011-03-20 Государственное образовательное учреждение высшего профессионального образования "Удмуртский государственный университет" Модификация альбумина совиалем как способ повышения его стабильности для производства фармацевтического биопрепарата альбумина в комплексе с гентамицином или стимаденом
MX2011002372A (es) * 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
JP6389236B2 (ja) * 2013-03-13 2018-09-12 ジェネンテック, インコーポレイテッド 酸化還元製剤

Also Published As

Publication number Publication date
HUE049707T2 (hu) 2020-11-30
BR112015022475A8 (pt) 2019-11-26
RU2707550C2 (ru) 2019-11-27
MX2015011433A (es) 2016-04-27
KR102317151B1 (ko) 2021-10-26
DK2968467T3 (da) 2020-08-10
CA2904169C (en) 2021-12-07
HRP20201161T1 (hr) 2020-11-13
PL2968467T3 (pl) 2020-10-19
JP6606059B2 (ja) 2019-11-13
KR20210040190A (ko) 2021-04-12
JP2016513667A (ja) 2016-05-16
ES2808823T3 (es) 2021-03-02
EP2968467B1 (en) 2020-06-03
KR102238379B1 (ko) 2021-04-09
WO2014160497A1 (en) 2014-10-02
CA2904169A1 (en) 2014-10-02
RU2019137020A (ru) 2021-01-14
EP2968467A4 (en) 2016-09-21
EP2968467A1 (en) 2016-01-20
PT2968467T (pt) 2020-07-28
KR20150130396A (ko) 2015-11-23
RS60534B1 (sr) 2020-08-31
HK1212613A1 (zh) 2016-06-17
CA3135558A1 (en) 2014-10-02
RU2015143549A (ru) 2017-04-20
JP2019167349A (ja) 2019-10-03
CN105209058A (zh) 2015-12-30
LT2968467T (lt) 2020-08-25
SI2968467T1 (sl) 2020-11-30
BR112015022475A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MY191169A (en) Anti-fcrh5 antibodies
HK1247854A1 (zh) 混合變應原組合物及其使用方法
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
WO2015038796A3 (en) Secretion of heme-containing polypeptides
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2019013560A (es) Formulaciones con oxidacion reducida.
SG10201913040SA (en) Compositions and methods for stabilizing flaviviruses with improved formulations
WO2015120062A8 (en) Therapeutic compounds and compositions
IN2015DN00127A (es)
PL3411432T3 (pl) Kompozycja wulkanizująca zawierająca cyklododekasiarkę i ulepszony związek cyklododekasiarki
PH12017502028A1 (en) Vortioxetine pyroglutamate
AR095398A1 (es) Formulaciones con oxidación reducida
EP3297440A4 (en) COMPOSITION WITH CARBOPLATIN AND USE
IN2014DN11078A (es)
SG10201900598TA (en) Factor viii formulation
EP3527225A4 (en) COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENT
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
EP3153492A4 (en) Novel compound and fragrance composition containing same
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
MX370416B (es) Formulaciones con oxidacion reducida.
EP3568203C0 (en) COMPOUNDS AND COMPOSITIONS
GB201614961D0 (en) Compounds and compositions for use
BR112017001483A2 (pt) “composições nutricionais contendo pó de fosfatidilserina”
EP3570833A4 (en) ANESTHETIC COMPOSITIONS AND PROCEDURES USING IMIDAZOLINE COMPOUNDS

Legal Events

Date Code Title Description
FG Grant or registration